Silverarc Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,876,407
| Closed | -$57.9M | – | 84 |
|
|
2026
Q1 | $57.9M | Buy |
2,876,407
+449,289
| +19% | +$7.24M | 5.91% | 2 |
|
|
2025
Q4 | $39.2M | Buy |
2,427,118
+1,063,740
| +78% | +$14.1M | 5.44% | 4 |
|
|
2025
Q3 | $16.6M | Sell |
1,363,378
-468,793
| -26% | -$6.48M | 2.24% | 15 |
|
|
2025
Q2 | $20.7M | Buy |
1,832,171
+133,187
| +8% | +$1.63M | 3.82% | 7 |
|
|
2025
Q1 | $19.6M | Buy |
1,698,984
+1,086,811
| +178% | +$11.1M | 4.01% | 6 |
|
|
2024
Q4 | $5.19M | Buy |
612,173
+37,615
| +7% | +$390K | 1.13% | 32 |
|
|
2024
Q3 | $6.65M | Buy |
574,558
+13,675
| +2% | +$172K | 1.49% | 20 |
|
|
2024
Q2 | $6.61M | Sell |
560,883
-300
| -0.1% | -$3.5K | 1.56% | 22 |
|
|
2024
Q1 | $6.66M | Buy |
561,183
+449,449
| +402% | +$5.99M | 1.85% | 20 |
|
|
2023
Q4 | $1.37M | Sell |
111,734
-117,200
| -51% | -$1.07M | 0.41% | 55 |
|
|
2023
Q3 | $2.2M | Sell |
228,934
-491,574
| -68% | -$5.02M | 0.67% | 44 |
|
|
2023
Q2 | $6.48M | Sell |
720,508
-3,036
| -0.4% | -$28K | 2.01% | 17 |
|
|
2023
Q1 | $5.69M | Buy |
+723,544
| New | +$5.4M | 2.35% | 15 |
|
|
2021
Q3 | – | Sell |
-14,882
| Closed | -$357K | – | 93 |
|
|
2021
Q2 | $357K | Sell |
14,882
-35,118
| -70% | -$919K | 0.16% | 86 |
|
|
2021
Q1 | $1.28M | Buy |
+50,000
| New | +$1.31M | 0.7% | 51 |
|
Other funds holding KALV
Silverarc Capital Management's KALV Position: Q2 2026 in Review
Silverarc Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 2,876,407 shares — an estimated $57.9M sold.
Silverarc Capital Management first reported a position in KALV in Q1 2021 and held it in 15 quarters. The position peaked at $57.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- Silverarc Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Silverarc Capital Management sold 2,876,407 KalVista Pharmaceuticals shares in Q2 2026, an estimated $57.9M.
- Silverarc Capital Management first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 15 quarters.
- Silverarc Capital Management's KalVista Pharmaceuticals position peaked at $57.9M in Q1 2026.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.